Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment.
作者信息
Wang Yu, Wang Min, Zhang Guanhua, Ou Xiaojuan, Ma Hong, You Hong, Jia Jidong
机构信息
Liver Research Center, Beijing Friendship Hospital, Capital Medical University; Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis; National Clinical Research Center for Digestive Diseases, Beijing, China.
出版信息
China CDC Wkly. 2020 Jul 31;2(31):596-600. doi: 10.46234/ccdcw2020.159.
Abstract
摘要
相似文献
1
Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment.
China CDC Wkly. 2020 Jul 31;2(31):596-600. doi: 10.46234/ccdcw2020.159.
2
Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: A multicentre perspective in China.
J Viral Hepat. 2018 Sep;25(9):1017-1025. doi: 10.1111/jvh.12903. Epub 2018 May 11.
3
China's efforts to shed its title of "Leader in liver disease".
Drug Discov Ther. 2007 Oct;1(2):84-5.
4
Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study.
Virol J. 2020 Aug 28;17(1):132. doi: 10.1186/s12985-020-01393-z.
5
Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
Value Health. 2008 Mar;11 Suppl 1:S11-22. doi: 10.1111/j.1524-4733.2008.00362.x.
6
China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B.
Scand J Public Health. 2020 Mar;48(2):233-239. doi: 10.1177/1403494818772188. Epub 2018 May 1.
7
Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
Clin Drug Investig. 2015 Mar;35(3):197-209. doi: 10.1007/s40261-015-0273-y.
8
Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
J Infect Dis. 2017 Aug 1;216(3):327-335. doi: 10.1093/infdis/jix295.
9
[Progress in prevention and control of viral hepatitis since the establishing of the People's Republic of China].
Zhonghua Gan Zang Bing Za Zhi. 2021 Aug 20;29(8):725-731. doi: 10.3760/cma.j.cn501113-20210722-00351.
10
Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
Clin Drug Investig. 2016 Aug;36(8):637-48. doi: 10.1007/s40261-016-0409-8.
引用本文的文献
1
Epidemiological trends and projections to 2035 of hepatitis B burden in China, 1990-2021.
PLoS One. 2025 Sep 2;20(9):e0330633. doi: 10.1371/journal.pone.0330633. eCollection 2025.
2
Comprehensive approach to controlling chronic hepatitis B in China.
Clin Mol Hepatol. 2024 Apr;30(2):135-143. doi: 10.3350/cmh.2023.0412. Epub 2024 Jan 5.
3
Time series analysis-based seasonal autoregressive fractionally integrated moving average to estimate hepatitis B and C epidemics in China.
World J Gastroenterol. 2023 Nov 14;29(42):5716-5727. doi: 10.3748/wjg.v29.i42.5716.
本文引用的文献
1
Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
Clin Infect Dis. 2021 Mar 1;72(5):743-752. doi: 10.1093/cid/ciaa134.
2
Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2582-2591.e6. doi: 10.1016/j.cgh.2020.03.001. Epub 2020 Mar 6.
3
[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].
Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):938-961. doi: 10.3760/cma.j.issn.1007-3418.2019.12.007.
4
Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B.
J Clin Transl Hepatol. 2019 Dec 28;7(4):322-328. doi: 10.14218/JCTH.2019.00052. Epub 2019 Dec 20.
5
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.
Hepatol Int. 2020 Jan;14(1):105-114. doi: 10.1007/s12072-019-10005-0. Epub 2020 Jan 3.
6
Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy.
Clin Gastroenterol Hepatol. 2020 Mar;18(3):719-727.e7. doi: 10.1016/j.cgh.2019.07.046. Epub 2019 Jul 27.
7
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.
Clin Gastroenterol Hepatol. 2020 Feb;18(2):457-467.e21. doi: 10.1016/j.cgh.2019.07.010. Epub 2019 Jul 12.
8
Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.
J Dig Dis. 2019 Sep;20(9):467-475. doi: 10.1111/1751-2980.12794. Epub 2019 Jul 21.
9
Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.
Hepatol Int. 2019 Sep;13(5):573-586. doi: 10.1007/s12072-019-09956-1. Epub 2019 Jun 6.
10
Roadmap to functional cure of chronic hepatitis B: An expert consensus.
J Viral Hepat. 2019 Oct;26(10):1146-1155. doi: 10.1111/jvh.13126. Epub 2019 Jun 19.
Zotero 插件